SGMO250117P2000
- 0.75
- 0.000.00%
Sangamo Therapeutics Newsroom
Gene Editing Stocks Drop as Intellia Announces Layoffs
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Jefferies Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $3
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Wells Fargo Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Cuts Target Price to $2
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership -- Barrons.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
US Equities Markets End Lower Tuesday In Last Trading Session of 2024
Sangamo Therapeutics Is Maintained at Buy by Jefferies
9 Analysts Have This To Say About Sangamo Therapeutics
Equity Markets Fall Intraday as 2024 Draws to Close
Top Midday Decliners
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations
Jefferies Initiates Sangamo Therapeutics(SGMO.US) With Buy Rating, Announces Target Price $3
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session